We retrospectively assessed the efficacy of T-DM1 compared with P + T + taxane in a cohort of metastatic HER2+ breast cancer patients, relapsed within 12 months from the end of (neo)adjuvant systemic therapy with CT ± trastuzumab. Here, ERBB2 is linked to breast carcinoma.